title banner

OR in the News

OR in the News (selected articles)

Sertcakacilar G, Bayrak SK, Pektas Y, Bostanci I, Yildiz GO, Sabaz MS: Evaluation of aerosol box use for ultrasound-guided internal jugular vein cannulation in patients with COVID-19: A short-term randomised study. Indian J Anaesth 2022; 66: 112-118

February 24, 2022

Background and Aims:
During the coronavirus disease 2019 (COVID‑19) pandemic, health care workers are at a high risk of infection from aerosols. In this study, we compared the ease of using the aerosol box (AB) with the traditional method during internal jugular vein cannulation attempts (IJVCA).
Methods:
The study included 40 patients with COVID‑19 who required central venous catheterisation during treatment in the ward. The patients were randomly allocated to one of the two protective equipment (PPE) groups and then randomly assigned to one of the five anaesthesiologists with at least 5 years of experience. Group P and A had both PPE and AB used, whereas Group P included patients where PPE was used alone. The physicians completed a survey after performing the procedure to evaluate the use of the AB.
Results:
The preparation for the procedure and procedure durations were observed to be statistically longer in Group P and A (P = 0.002 and P = 0.001, respectively). The first attempt in Group P and A was unsuccessful in six patients, whereas the first attempt in Group P was unsuccessful in only two patients (P = 0.235). Anaesthesiologists described difficulty with manipulation during the procedure, discomfort using the box, and resulting cognitive load increase in Group P and A.
Conclusion:
The IJVCA procedures were faster and easier and had greater satisfaction for physicians when the AB was not used. Also, the high complication rate, including carotid artery punctures and disruption of sterility and PPE, albeit not statistically significant, has clinical implications. Therefore, we do not recommend the use of ABs for IJVCA.
Key words:
Aerosols, catheterisation, central venous, COVID‑19, personal protective equipment, SARS‑CoV‑2